A recent survival data analysis of 987,934 cases from the national cancer database (with a median follow-up of 54 months) demonstrated that HER2-low only marginally improves prognosis (HR = 0.98 (0.97–0.99), p < 0.001) (Peiffer et al., 2023). This evidence concerns the gene ERBB2 and cancer.